Pediatric Obesity: GLP-1 Agonist Approval and Multidisciplinary Management
Epidemiology and Classification
Pediatric overweight is defined as BMI at the 85th-94th percentile for age and sex, obesity as BMI at or above the 95th percentile, and severe obesity as BMI at or above 120% of the 95th percentile. The AAP 2023 Clinical Practice Guideline for the Evaluation and Treatment of Children and Adolescents with Obesity represents the first comprehensive guideline update in 15 years, replacing the previous watch-and-wait approach with early intensive intervention. Comorbidity screening should begin at diagnosis and include fasting lipid panel, fasting glucose and HbA1c, ALT, and blood pressure measurement at every visit.
Intensive Behavioral Interventions
The AAP guideline recommends Intensive Health Behavior and Lifestyle Treatment (IHBLT) as first-line therapy for all children with obesity, defined as a minimum of 26 contact hours over 3-12 months. The US Preventive Services Task Force gives this a B recommendation based on meta-analysis showing BMI reduction of 0.7-1.0 kg/m² with comprehensive behavioral interventions. The CIRCUIT Program at the Montreal Heart Institute demonstrated that intensive family-based intervention (dietitian, exercise physiologist, psychologist) reduced BMI z-score by 0.24 at 2 years. However, accessibility remains a barrier, with fewer than 50% of eligible children having access to IHBLT programs.
GLP-1 Receptor Agonists: Semaglutide and Liraglutide
Semaglutide 2.4 mg weekly (Wegovy) received FDA approval for adolescents aged 12 and older with obesity in December 2022. The STEP TEENS trial demonstrated a BMI reduction of 16.1% versus a 0.6% increase with placebo at 68 weeks (estimated treatment difference -16.7 percentage points, p<0.001). Liraglutide 3.0 mg daily was previously approved for ages 12 and older based on a trial showing 2.65% BMI reduction versus 1.56% increase with placebo. Gastrointestinal side effects (nausea, vomiting, diarrhea) are the most common, occurring in 40-60% of patients, though most are transient and mild-to-moderate.
Sponsored
Metabolic and Bariatric Surgery in Adolescents
The AAP now recommends evaluation for metabolic and bariatric surgery for adolescents aged 13 and older with severe obesity (BMI at or above 120% of the 95th percentile) or with BMI at or above the 95th percentile with significant comorbidities. The Teen-LABS study provides long-term outcomes: at 5 years post-Roux-en-Y gastric bypass, mean BMI decrease was 29%, with type 2 diabetes remission in 86% and hypertension remission in 68%. Vertical sleeve gastrectomy, now the most commonly performed procedure in adolescents, achieves comparable short-term weight loss with lower complication rates (8% versus 15% for RYGB at 30 days).
Integrated Treatment Algorithm
A staged approach integrates all treatment modalities: IHBLT should be initiated at diagnosis for all children aged 6 and older. Pharmacotherapy (GLP-1 agonists, or phentermine/topiramate for ages 12 and older) is added if insufficient response after 3-6 months of behavioral intervention or if comorbidities require more aggressive management. Surgical evaluation should occur in parallel with medical management for adolescents meeting criteria. Throughout treatment, monitoring includes quarterly anthropometric assessment, annual cardiometabolic labs, psychosocial screening for disordered eating (using the EDE-Q), and nutritional sufficiency panels for patients on GLP-1 agonists or post-surgery.
Sponsored
Want to try Ailva?
Ailva is a clinical intelligence platform that delivers evidence-based answers with verified citations and cross-system reasoning. Free for all NPI holders.